Thermo Fisher Scientific acknowledges the value of supporting independent research projects in order to promote
excellence in molecular diagnostics.
The Oncomine Clinical Research Grant Program will be accepting proposals for the following focus areas:
Submissions are currently closed. Please check back in August.
We will accept applications via the submission portal or via email (email@example.com). Please visit this web page during the open submission period to submit your application.
The Oncomine Clinical Research Grant Program supports investigator-initiated studies (IIS) and education projects, on molecular profiling in oncology, with the goal to increase high quality molecular profiling and to help democratize the future of precision medicine.
Proposal reviews are conducted by independent and internationally recognized experts together with Thermo Fisher Scientific medical and scientific leadership. Funding is considered based on scientific merit.
The application process is managed by the Oncomine Clinical Research Grant Office, part of the Medical Affairs team of the Clinical Sequencing Division at Thermo Fisher Scientific. For detailed information about how to apply, including documentation requirements, review process, and decision notification, refer to the Guidelines for Applicants.
Grant applications should be submitted electronically (English only) using the specific Proposal Form. Proposals should outline the planned activities to be performed within a maximum of 12 months. A budget is required for every grant request and should detail the proposed use of requested funds. The maximum budget request for each project is set at $200,000.
We thank all applicants that submitted projects across our 2021 calls for applications.
We are pleased to announce the 2021 grant awardees below.
“Prognostic value of minimal residual disease monitoring by comprehensive next-generation sequencing in pediatric acute myeloid leukemia”
“Characterizing Prostate Cancer Plasticity Relative to Lethal Disease, Neuroendocrine Differentiation and Therapeutic Resistance”
“Ultrafast next generation sequencing: Universal Testing Of Patients with Infiltrating Adenocarcinomas of the Lung”
“Homologous recombination deficiency (HRD) testing in high-grade serous carcinoma using peritoneal effusion samples”
“TCR repertoire in combination with HLA and TMB as predictor of response to immune checkpoint blockade in melanoma and lung cancer”
“Dissecting the tumor immune microenvironment of breast cancer during pregnancy”
“Analyses of the role of immune-host cell interactions in defining different brain metastases patterns in NSCLC”
"Predictive biomarker for metastatic melanoma patients treated with immune checkpoint inhibitors"
Beatriz Bellosillo - Head of Molecular Diagnostics Section, Pathology Department
Edurne Arriola - Head of the Thoracic and Genitourinary Section
“Receiving the grant from Thermo Fisher to assess the role of liquid biopsy in Small cell Lung cancer will allow to discover novel biomarkers and therapeutic avenues in a disease with urgent clinical needs.”
Giulia Siravegna, PhD - Instructor in Medicine Harvard Medical School, Department of Medicine, Research staff, Massachusetts General Hospital Cancer Center
“This grant will allow the characterization of circulating free tumor DNA (ctDNA) isolated from ascites fluid in gastric cancer patients and its comparison it with matched peripheral blood ctDNA, as well as primary tumor samples to identify peritoneal/ascites-specific targets. The use of ascitic fluid as a source for predictive and prognostic biomarkers is itself highly innovative and allows for rapid clinical translation as material is routinely sampled in clinical care.”
Leomar Ballester - Assistant Professor, Molecular Genetic Pathology and Neuropathology
Co-Director, Molecular Diagnostics Laboratory, Department of Pathology and Laboratory Medicine, Department of Neurosurgery
“The Oncomine Clinical Research Grant will facilitate our development of a cerebrospinal fluid liquid biopsy assay to incorporate precision medicine strategies in the management of patients with primary and metastatic central nervous system tumors. The Genexus System could provide the necessary sensitivity and specificity to enhance current methods for evaluating the potential of targeted therapies for patients.”
Professor Stephen Fox - Director of Pathology and Head of the Molecular Pathology Laboratory, at Peter Mac in Melbourne, Australia
"This grant will enable us to provide circulating tumour (ct) DNA testing to patients with non-small cell lung cancer in rural and remote parts of Victoria, Australia, where outcomes are poorer for this cancer. We will be able to rapidly identify mutations in ctDNA and deliver coordinated specialized oncology care to these patients. The goal is to determine whether liquid biopsies can replace tumour biopsies for selecting patients for the most appropriate treatment."
For any questions about the Oncomine Clinical Research Grant Program, please email firstname.lastname@example.org